Investment
BioInvent discusses recent Pfizer immunotherapy alliance

Three years after setting out to turn BioInvent around, company president and CEO Michael Oredsson tells Mike Ward, Informa Pharma Intelligence’s insights global director of content, how the company is developing its immunotherapy offering. With tumor-associated myeloid cells, BioInvent secured a deal with Pfizer at the end of 2016, while it intends to go it alone with its regulatory T cell approach.
Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Michael Oredsson – President and CEO, BioInvent